Fig. 4: Associations of response with clinical parameters. | npj Breast Cancer

Fig. 4: Associations of response with clinical parameters.

From: A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Fig. 4: Associations of response with clinical parameters.

Intervals represent the 80% confidence interval of the point estimate of response rate. PD-L1: programmed death ligand 1; CPS combined positive score, TIL tumor-infiltrating lymphocytes, ALC absolute lymphocyte count, RECIST response evaluation criteria in solid tumors, *(neo)-adjuvant systemic therapy counted as one line if received <6 months from study enrollment.

Back to article page